Examkin

Soru

Zorluk: OrtaEnd-of-Life and Palliative Care

A 76-year-old man with metastatic prostate cancer and stage 4 chronic kidney disease is admitted to the hospital for management of severe, intractable bone pain. He is started on escalating doses of oral morphine. Over the next 48 hours, his pain control improves, but he develops worsening confusion, visual hallucinations, and frequent myoclonic jerks in his upper extremities. The patient's daughter, who is his designated healthcare proxy, is very distressed by these new symptoms. She demands that all opioid medications be stopped immediately, stating they are "destroying his brain." The patient is currently disoriented to time and place and cannot participate in medical decision-making. Which of the following is the most appropriate next step in management?

  1. Discontinue oral morphine and initiate intravenous fentanylCevap
  2. B
    Request a psychiatric consultation to determine the patient's legal competence to make his own medical decisions
  3. C
    Continue the current morphine regimen and administer intravenous haloperidol
  4. D
    Discharge the patient to a skilled nursing facility to undergo intensive cognitive rehabilitation
  5. E
    Withhold all opioid medications and initiate high-dose ibuprofen

Cevap

Discontinue oral morphine and initiate intravenous fentanyl.
The correct action is to discontinue the offending agent (morphine) and rotate to a different opioid that is safe in renal impairment, such as fentanyl. The patient is experiencing opioid-induced neurotoxicity (OIN), a well-known complication in patients with chronic kidney disease (CKD) who receive morphine. Morphine is hepatically metabolized into active metabolites, primarily morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), which are excreted by the kidneys. In the setting of severe CKD, M3G accumulates, crosses the blood-brain barrier, and causes significant neuroexcitatory effects including myoclonus, hyperalgesia, hallucinations, and delirium. The most appropriate clinical step is to explain the phenomenon to the distressed healthcare proxy and switch the patient's analgesia to an opioid that lacks active, renally cleared toxic metabolites, such as fentanyl or methadone. This relieves the toxicity while continuing to palliate the patient's severe cancer pain.

Adım Adım Çözüm

1
Identify the acute clinical syndrome based on the patient's new symptoms.
The new onset of confusion, visual hallucinations, and myoclonic jerks in the setting of recent opioid escalation points to opioid-induced neurotoxicity (OIN).
Recognizing OIN is crucial because it requires a specific modification of the analgesic regimen rather than simply adding antipsychotics.
2
Correlate the syndrome with the patient's underlying comorbidities.
The patient has stage 4 chronic kidney disease. Morphine is metabolized to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), which rely on renal clearance.
In CKD, the neuroexcitatory metabolite M3G accumulates, crossing the blood-brain barrier and causing the observed myoclonus and delirium.
3
Determine the most appropriate management for the patient and the surrogate's concerns.
The treatment for OIN is opioid rotation. A safe opioid for patients with severe renal impairment (like fentanyl or methadone) must be initiated.
Stopping all opioids as the daughter requested would precipitate a severe pain crisis and withdrawal. Educating the daughter while rotating to a renal-safe opioid like fentanyl addresses both the toxicity and the underlying pain.

Anahtar Kavram

Management of Opioid-Induced Neurotoxicity in Chronic Kidney Disease
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru